All News
Filter News
Found 507,016 articles
-
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
-
Purdue Pharma, best known for selling painkiller OxyContin, announced it laid off approximately 350 staffers.
-
It’s a super-busy week for biotech initial public offerings (IPOs) with six companies raking in a total of around $568 million.
-
Former Puma Biotechnology Executive Sentenced to More than Two Years in Prison for Insider Trading
6/21/2018
Robert Gadimian, a former executive with Puma Biotechnology, was sentenced to more than two years in prison for insider trading. -
A new report highlights some concerns about the long-term commercial viability of game-changing gene therapies that can radically transform the lives of patients.
-
Shares of Incyte Corporation are up slightly this morning after the company started off its annual R&D day with positive news from its pivotal REACH1 study of Jakafi (ruxolitinib) in steroid-refractory acute graft-versus-host disease (GVHD) and sets up the filing of a supplemental New Drug Applic...
-
Novo Nordisk’s semaglutide, an oral GLP-1 analogue, continues to rack up positive Phase III clinical trial data compared to its competitors.
-
Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801
6/21/2018
Up to 48 subjects will be enrolled including 24 healthy volunteers and 24 subjects with type 1 diabetes.
-
Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation
6/21/2018
HTX-011 Significantly Reduced Both Pain Intensity and Opioid Use in Patients Undergoing Total Knee Arthroplasty
-
Alligator Bioscience's ATOR-1017 Strongly Activates Both T cells and NK Cells, Important for the Effective Eradication of Tumor Cells
6/21/2018
Further preclinical findings support a best-in-class profile
-
Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal Stromal Tumors
6/21/2018
-- VOYAGER trial to evaluate avapritinib versus regorafenib in third- and fourth-line GIST --
-
Caris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study
6/21/2018
Leveraging ADAPT Biotargeting System would have significantly increased the probability of success
-
Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi®) in Steroid-Refractory Acute Graft-Versus-Host Disease
6/21/2018
Results support planned sNDA submission in 2018
-
Performance Validation Inc. Announces the Launch of Critical Airflow Visualization Services
6/21/2018
FDA inspectors will review the video recordings of smoke study tests to verify unidirectional airflow and sweeping action over and away from the product.
-
NOCDURNA® (desmopressin acetate) Now Approved by U.S. FDA as First Sublingual Tablet to Treat Nocturia due to Nocturnal Polyuria
6/21/2018
The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market NOCDURNA®.
-
Vertex’s Paul Negulescu Awarded the Warren Alpert Foundation Prize for Pioneering Discoveries in Cystic Fibrosis
6/21/2018
Vertex Pharmaceuticals Incorporated today announced that Senior Vice President Paul Negulescu has been named one of the winners of this year’s Warren Alpert Foundation Prize.
-
AngioDynamics to Report Fiscal 2018 Fourth Quarter and Full-Year Financial Results on July 11, 2018
6/21/2018
AngioDynamics today announced that it will report financial results for the fourth quarter and fiscal year 2018 before the market open on Wednesday, July 11, 2018.
-
Levo Therapeutics Announces Publication of Phase 2 Study Results and Planned Phase 3 Study of Intranasal Carbetocin for the Treatment of Prader-Willi Syndrome
6/21/2018
Levo Therapeutics Inc. announced today that JCI Insight has published the results of a Phase 2 study of intranasal carbetocin (LV-101).
-
Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease
6/21/2018
Program Designed to Support U.S. Regulatory Filing of IW-3718 as Potential Treatment for Patients Who Continue to Suffer From GERD Despite Receiving Standard of Care.
-
Tandem Diabetes Care Announces FDA Approval of t:slim X2 Insulin Pump with Basal-IQ Technology
6/21/2018
New Predictive Low Glucose Suspend Feature to Launch with Dexcom G6 CGM System Integration.